PL2576624T3 - Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych - Google Patents
Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznychInfo
- Publication number
- PL2576624T3 PL2576624T3 PL11786091T PL11786091T PL2576624T3 PL 2576624 T3 PL2576624 T3 PL 2576624T3 PL 11786091 T PL11786091 T PL 11786091T PL 11786091 T PL11786091 T PL 11786091T PL 2576624 T3 PL2576624 T3 PL 2576624T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- recombinant human
- neurological diseases
- csf dimer
- csf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101816235A CN102260343A (zh) | 2010-05-25 | 2010-05-25 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2576624T3 true PL2576624T3 (pl) | 2017-02-28 |
Family
ID=45003325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11786091T PL2576624T3 (pl) | 2010-05-25 | 2011-05-25 | Dimer rekombinowanego ludzkiego G-CSF i jego zastosowanie w leczeniu chorób neurologicznych |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8557546B2 (pl) |
| EP (2) | EP2576624B1 (pl) |
| JP (1) | JP6114186B2 (pl) |
| CN (3) | CN102260343A (pl) |
| AU (1) | AU2011257734B2 (pl) |
| CA (1) | CA2800688C (pl) |
| DK (2) | DK2576624T3 (pl) |
| ES (2) | ES2611151T3 (pl) |
| FI (1) | FIC20240027I1 (pl) |
| FR (1) | FR24C1032I1 (pl) |
| HU (2) | HUE031872T2 (pl) |
| NL (1) | NL301285I2 (pl) |
| PL (1) | PL2576624T3 (pl) |
| PT (1) | PT2576624T (pl) |
| WO (1) | WO2011147319A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380090A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
| JP5947891B2 (ja) * | 2011-07-25 | 2016-07-06 | ジェネロン（シャンハイ）コーポレイション リミテッドＧｅｎｅｒｏｎ （Ｓｈａｎｇｈａｉ） Ｃｏｒｐｏｒａｔｉｏｎ Ｌｔｄ． | 神経変性疾患を治療する医薬品の製造におけるｇ−ｃｓｆ二量体の応用 |
| CN103717614A (zh) | 2011-08-09 | 2014-04-09 | 普罗法尔马封闭式股份公司 | 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法 |
| US9359374B2 (en) * | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| LT6161B (lt) * | 2013-09-27 | 2015-06-25 | Uab Profarma | Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas |
| EP2957294A1 (en) * | 2014-06-20 | 2015-12-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | GCSF for use in the treatment of neurogenic immune suppression and/or prevention of related medical complications |
| CN113480667B (zh) * | 2021-08-17 | 2023-03-28 | 长春萤火虫生物科技有限公司 | 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用 |
| WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3954004B2 (ja) | 1991-12-26 | 2007-08-08 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| EP0807181A1 (en) | 1995-02-03 | 1997-11-19 | G.D. Searle & Co. | NOVEL c-MPL LIGANDS |
| US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
| EP1131333B1 (en) | 1998-10-26 | 2010-06-02 | Wyeth a Corporation of the State of Delaware | ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
| US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| GB0024442D0 (en) | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
| EP1334127A1 (en) * | 2000-11-02 | 2003-08-13 | Maxygen Aps | Single-chain multimeric polypeptides |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| AU2003210806A1 (en) * | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| ATE544463T1 (de) | 2004-11-05 | 2012-02-15 | Univ Northwestern | Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen |
| CN100515491C (zh) | 2005-01-04 | 2009-07-22 | 健能隆医药技术（上海）有限公司 | 白介素-22的医药用途 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| WO2008137571A1 (en) | 2007-05-01 | 2008-11-13 | Florida Atlantic University | Methods of treating neurodegenerative diseases |
| WO2008147534A1 (en) | 2007-05-22 | 2008-12-04 | Maxygen Holdings Ltd. | Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| EP3173484B1 (en) * | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| US20110182848A1 (en) | 2007-08-03 | 2011-07-28 | Asterion Limited | Granulocyte colony stimulating factor |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| CN104888193A (zh) | 2007-11-07 | 2015-09-09 | 健泰科生物技术公司 | 用于治疗微生物病症的组合物和方法 |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| EP2523689A4 (en) | 2010-01-13 | 2013-09-11 | Amgen Inc | IL-22-FC WITH HEPCIDINE EFFECT |
| LT2010013A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas |
| LT2010012A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380090A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
| JP5947891B2 (ja) | 2011-07-25 | 2016-07-06 | ジェネロン（シャンハイ）コーポレイション リミテッドＧｅｎｅｒｏｎ （Ｓｈａｎｇｈａｉ） Ｃｏｒｐｏｒａｔｉｏｎ Ｌｔｄ． | 神経変性疾患を治療する医薬品の製造におけるｇ−ｃｓｆ二量体の応用 |
-
2010
- 2010-05-25 CN CN2010101816235A patent/CN102260343A/zh active Pending
-
2011
- 2011-05-23 US US13/114,035 patent/US8557546B2/en active Active
- 2011-05-25 DK DK11786091.6T patent/DK2576624T3/en active
- 2011-05-25 EP EP11786091.6A patent/EP2576624B1/en active Active
- 2011-05-25 PL PL11786091T patent/PL2576624T3/pl unknown
- 2011-05-25 EP EP16185991.3A patent/EP3121198B1/en active Active
- 2011-05-25 DK DK16185991T patent/DK3121198T3/da active
- 2011-05-25 PT PT117860916T patent/PT2576624T/pt unknown
- 2011-05-25 AU AU2011257734A patent/AU2011257734B2/en active Active
- 2011-05-25 CN CN201180025773.XA patent/CN102906120B/zh active Active
- 2011-05-25 HU HUE11786091A patent/HUE031872T2/en unknown
- 2011-05-25 ES ES11786091.6T patent/ES2611151T3/es active Active
- 2011-05-25 ES ES16185991T patent/ES2750730T3/es active Active
- 2011-05-25 CN CN201510112334.2A patent/CN104710535B/zh active Active
- 2011-05-25 WO PCT/CN2011/074678 patent/WO2011147319A1/en active Application Filing
- 2011-05-25 JP JP2013511527A patent/JP6114186B2/ja active Active
- 2011-05-25 CA CA2800688A patent/CA2800688C/en active Active
-
2013
- 2013-08-30 US US14/014,413 patent/US9273108B2/en active Active
-
2024
- 2024-07-22 HU HUS2400027C patent/HUS2400027I1/hu unknown
- 2024-07-24 FR FR24C1032C patent/FR24C1032I1/fr active Active
- 2024-07-24 NL NL301285C patent/NL301285I2/nl unknown
- 2024-07-30 FI FIC20240027C patent/FIC20240027I1/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3121198A1 (en) | 2017-01-25 |
| CN102906120A (zh) | 2013-01-30 |
| CA2800688C (en) | 2018-05-15 |
| CN104710535A (zh) | 2015-06-17 |
| AU2011257734B2 (en) | 2015-06-11 |
| JP6114186B2 (ja) | 2017-04-12 |
| ES2750730T3 (es) | 2020-03-26 |
| CN102906120B (zh) | 2015-03-04 |
| CA2800688A1 (en) | 2011-12-01 |
| PT2576624T (pt) | 2016-10-31 |
| NL301285I2 (nl) | 2024-08-21 |
| EP2576624A4 (en) | 2013-11-13 |
| HUS2400027I1 (hu) | 2024-08-28 |
| DK2576624T3 (en) | 2016-11-14 |
| US9273108B2 (en) | 2016-03-01 |
| CN102260343A (zh) | 2011-11-30 |
| ES2611151T3 (es) | 2017-05-05 |
| HUE031872T2 (en) | 2017-08-28 |
| DK3121198T3 (da) | 2019-10-28 |
| EP3121198B1 (en) | 2019-08-14 |
| FR24C1032I1 (fr) | 2024-08-30 |
| EP2576624A1 (en) | 2013-04-10 |
| AU2011257734A1 (en) | 2012-12-20 |
| US20110293554A1 (en) | 2011-12-01 |
| US8557546B2 (en) | 2013-10-15 |
| WO2011147319A1 (en) | 2011-12-01 |
| US20140004076A1 (en) | 2014-01-02 |
| JP2013530148A (ja) | 2013-07-25 |
| EP2576624B1 (en) | 2016-08-31 |
| FIC20240027I1 (fi) | 2024-07-30 |
| CN104710535B (zh) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400027I1 (hu) | Rekombináns humán G-CSF dimer és alkalmazása, neurológiai betegségek kezelésében | |
| HK1258028A1 (zh) | 人類抗體及其在神經疾病治療中的診斷和治療用途 | |
| HRP20160714T1 (hr) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| HK1219092A1 (zh) | 用於治療癌症和免疫以及自身免疫性疾病的細胞凋亡誘導劑 | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| PH12013500892A1 (en) | Composition for use in the prevention and/or treatment of skin conditions and skin diseases | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| HK1183866A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| EP2621501A4 (en) | POLYCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS FOR THEIR USE IN THE TREATMENT OF VIRAL DISEASES | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| EP2528603A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | |
| HK1184370A1 (zh) | 用於治療疼痛的藥物組合 | |
| EP2612676A4 (en) | USE OF A G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA | |
| EP2616094A4 (en) | TREATMENT OF BRAIN INJURIES THROUGH IMPORTS | |
| EP2624821A4 (en) | POLYTHERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES | |
| EP2949651A4 (en) | SUBSTITUTED BENZOTHIAZOLES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF HUMAN DISEASES | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| PT2555790T (pt) | USO TERAPÊUTICO DA PROTEÍNA DE ß MICROGLOBULINA | |
| HK1214771A1 (zh) | 用於治療皮膚病的製劑 | |
| IL204097A0 (en) | Medicine for the treatment of skin cancer |